Portola Pharmaceuticals’ (PTLA) “Neutral” Rating Reaffirmed at Credit Suisse Group

Credit Suisse Group reissued their neutral rating on shares of Portola Pharmaceuticals (NASDAQ:PTLA) in a research note published on Wednesday morning, Briefing.com Automated Import reports.

Several other analysts also recently issued reports on the stock. Cowen reissued a buy rating and set a $149.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, May 8th. Zacks Investment Research downgraded shares of Hersha Hospitality Trust from a buy rating to a hold rating in a research note on Thursday, May 2nd. BidaskClub downgraded shares of ZIX from a strong-buy rating to a buy rating in a research note on Tuesday, May 21st. William Blair reissued an outperform rating on shares of Portola Pharmaceuticals in a research note on Monday, June 17th. Finally, ValuEngine downgraded shares of Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Portola Pharmaceuticals presently has an average rating of Hold and an average target price of $42.29.

Shares of NASDAQ:PTLA traded down $0.59 on Wednesday, reaching $26.16. 966,392 shares of the company traded hands, compared to its average volume of 1,252,389. Portola Pharmaceuticals has a fifty-two week low of $14.81 and a fifty-two week high of $42.17. The firm has a 50 day simple moving average of $27.31. The stock has a market cap of $1.81 billion, a PE ratio of -5.22 and a beta of 2.23. The company has a debt-to-equity ratio of 5.15, a current ratio of 4.81 and a quick ratio of 4.77.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.02). Portola Pharmaceuticals had a negative net margin of 618.46% and a negative return on equity of 238.48%. The company had revenue of $22.17 million for the quarter, compared to the consensus estimate of $20.60 million. During the same period in the previous year, the business earned ($1.28) EPS. The company’s revenue was up 233.9% on a year-over-year basis. As a group, research analysts forecast that Portola Pharmaceuticals will post -4.13 earnings per share for the current fiscal year.

In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $34.45, for a total transaction of $172,250.00. Following the sale, the director now directly owns 14,000 shares of the company’s stock, valued at approximately $482,300. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.50% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Portola Pharmaceuticals by 0.4% in the fourth quarter. BlackRock Inc. now owns 5,326,939 shares of the biopharmaceutical company’s stock worth $103,982,000 after acquiring an additional 19,532 shares during the last quarter. William Blair Investment Management LLC increased its stake in shares of Portola Pharmaceuticals by 41.7% in the first quarter. William Blair Investment Management LLC now owns 4,154,870 shares of the biopharmaceutical company’s stock worth $144,174,000 after acquiring an additional 1,222,057 shares during the last quarter. Fiera Capital Corp acquired a new position in shares of Portola Pharmaceuticals in the first quarter worth $53,590,000. Brandywine Global Investment Management LLC increased its stake in shares of Portola Pharmaceuticals by 11.8% in the fourth quarter. Brandywine Global Investment Management LLC now owns 834,967 shares of the biopharmaceutical company’s stock worth $16,299,000 after acquiring an additional 87,999 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Portola Pharmaceuticals by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 730,249 shares of the biopharmaceutical company’s stock worth $14,254,000 after acquiring an additional 33,734 shares during the last quarter.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

Featured Story: Inflation

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.